Pharma Two B has raised $30 million to complete a phase 3 trial of its Parkinson’s asset P2B001 and added ex-Pfizer CEO Jeff Kindler to its board.

Exonics Therapeutics has won $5 million in seed funding toward its goal of using cutting-edge new gene editing technology to help correct the majority of DMD…

La Jolla Pharmaceutical has posted positive top-line data from its late-stage trial of LJPC-501 in patients with a severe heart condition known as…

Merck & Co.'s decision to write down the value of hepatitis C drug therapy uprifosbuvir reportedly comes on the back of regulatory requests for…

Held up last year at the FDA by manufacturing issues, AstraZeneca has been granted a much-needed recommendation from the EMA for its $2.7 billion hyperkalemia…

Roche has revealed that a patient died in a phase 3 hemophilia trial of bispecific antibody emicizumab.

In an unexpected announcement made after hours last night, Big Biotech Celgene said one of its top execs, Jacqualyn Fouse, would be “retiring” in the summer…

Johnson & Johnson Innovation has led a $25 million Series A in targeted cancer radiotherapeutic startup Fusion Pharmaceuticals.

Aveo inches closer to completing a crucial trial of its main asset tivozanib—almost four years after the FDA turned down the kidney cancer drug.

Biotech